Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Short term Debt (2023 - 2025)

Profound Medical has reported Short term Debt over the past 3 years, most recently at $4.5 million for Q3 2025.

  • Quarterly results put Short term Debt at $4.5 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $4.5 million (changed N/A YoY), and the annual figure for FY2024 was $1.7 million, down 17.44%.
  • Short term Debt for Q3 2025 was $4.5 million at Profound Medical, up from $1.7 million in the prior quarter.
  • Over the last five years, Short term Debt for PROF hit a ceiling of $4.5 million in Q3 2025 and a floor of $1.7 million in Q4 2024.
  • Median Short term Debt over the past 3 years was $2.1 million (2023), compared with a mean of $2.8 million.
  • Peak annual rise in Short term Debt hit 17.44% in 2024, while the deepest fall reached 17.44% in 2024.
  • Profound Medical's Short term Debt stood at $2.1 million in 2023, then fell by 17.44% to $1.7 million in 2024, then skyrocketed by 157.92% to $4.5 million in 2025.
  • The last three reported values for Short term Debt were $4.5 million (Q3 2025), $1.7 million (Q4 2024), and $2.1 million (Q4 2023) per Business Quant data.